

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and LMEADLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12 APR 26 PROMT: New display field available
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 14 APR 26 LITAlert now available on STN
NEWS 15 APR 27 NLDB: New search and display fields available
NEWS 16 May 10 PROUSDDR now available on STN
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May
and June 2004
NEWS 18 May 12 EXTEND option available in structure searching
NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20 May 17 FRFULL now available on STN

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:05:29 ON 27 MAY 2004

=> file medline, uspatful, dgene, embase, wpids, fsta,		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 11:06:03 ON 27 MAY 2004

FILE 'USPATFULL' ENTERED AT 11:06:03 ON 27 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:06:03 ON 27 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 11:06:03 ON 27 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:06:03 ON 27 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 11:06:03 ON 27 MAY 2004
COPYRIGHT (C) 2004 International Food Information Service

=> sMC148P or molluscum contagiosum viral protein
SMC148P IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s MC148P or molluscum contagiosum viral protein
L1 6 MC148P OR MOLLUSCUM CONTAGIOSUM VIRAL PROTEIN

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 6 USPATFULL on STN
TI Atopic dermatitis treatment method
AB Compositions are provided for treating atopic dermatitis, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from Molluscum Contagiosum Virus (MCV), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of MCV proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other **MC148P** type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other **MC148P** type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to MCV proteings so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:16613 USPATFULL
TITLE: Atopic dermatitis treatment method
INVENTOR(S): Paslin, David A., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		

NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 6 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by
administering **MC148P** proteins from Molluscum Contagiosum Virus

AN AAU76904 Protein DGENE
AB This invention relates to a novel method for treating atopic dermatitis,
other atopic diseases and other inflammatory and/or allergic skin
disorders. The method comprises administering a molluscum contagiosum
Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3)
MC148P. The method of the invention may have dermatological,
anti-allergic, anti-inflammatory and anti-asthmatic activities. The
MC148P protein is administered to treat atopic dermatitis, other
atopic diseases and other inflammatory and/or allergic skin disorders.
The present sequence represents the molluscum contagiosum virus MC148
type 2 protein used in the method of the invention.

ACCESSION NUMBER: AAU76904 Protein DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin
disorders by administering **MC148P** proteins from
Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: N-PSDB: ABK10280
DESCRIPTION: Molluscum contagiosum virus MCV148 type 2 protein.

L1 ANSWER 3 OF 6 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by
administering **MC148P** proteins from Molluscum Contagiosum Virus

AN AAU76903 Protein DGENE
AB This invention relates to a novel method for treating atopic dermatitis,
other atopic diseases and other inflammatory and/or allergic skin
disorders. The method comprises administering a molluscum contagiosum
Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3)
MC148P. The method of the invention may have dermatological,
anti-allergic, anti-inflammatory and anti-asthmatic activities. The
MC148P protein is administered to treat atopic dermatitis, other
atopic diseases and other inflammatory and/or allergic skin disorders.
The present sequence represents the molluscum contagiosum virus MC148
type I protein used in the method of the invention.

ACCESSION NUMBER: AAU76903 Protein DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin
disorders by administering **MC148P** proteins from
Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English

OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: N-PSDB: ABK10279
DESCRIPTION: Molluscum contagiosum virus MCV148 type I protein.

L1 ANSWER 4 OF 6 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by
administering **MC148P** proteins from Molluscum Contagiosum Virus

AN ABK10280 DNA DGENE
AB This invention relates to a novel method for treating atopic dermatitis,
other atopic diseases and other inflammatory and/or allergic skin
disorders. The method comprises administering a molluscum contagiosum
Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3)
MC148P. The method of the invention may have dermatological,
anti-allergic, anti-inflammatory and anti-asthmatic activities. The
MC148P protein is administered to treat atopic dermatitis, other
atopic diseases and other inflammatory and/or allergic skin disorders.
The present sequence represents the cDNA encoding the molluscum
contagiosum virus MC148 type 2 protein used in the method of the
invention. This sequence corresponds to nucleotides 166,992 - 167,303 of
the MCV genome.

ACCESSION NUMBER: ABK10280 DNA DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin
disorders by administering **MC148P** proteins from
Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: P-PSDB: AAU76904
DESCRIPTION: cDNA encoding molluscum contagiosum virus MCV148 type 2
protein.

L1 ANSWER 5 OF 6 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by
administering **MC148P** proteins from Molluscum Contagiosum Virus

AN ABK10279 DNA DGENE
AB This invention relates to a novel method for treating atopic dermatitis,
other atopic diseases and other inflammatory and/or allergic skin
disorders. The method comprises administering a molluscum contagiosum
Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3)
MC148P. The method of the invention may have dermatological,
anti-allergic, anti-inflammatory and anti-asthmatic activities. The
MC148P protein is administered to treat atopic dermatitis, other
atopic diseases and other inflammatory and/or allergic skin disorders.
The present sequence represents the cDNA encoding the molluscum
contagiosum virus MC148 type I protein used in the method of the
invention. This sequence corresponds to nucleotides 166,992-167,303 of
the MCV genome.

ACCESSION NUMBER: ABK10279 DNA DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin
disorders by administering **MC148P** proteins from
Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022

US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: P-PSDB: AAU76903
DESCRIPTION: cDNA encoding molluscum contagiosum virus MCV148 type I protein.

L1 ANSWER 6 OF 6 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus.
AN 2002-138958 [18] WPIDS
AB US2002009489 A UPAB: 20020319

NOVELTY - A method and kit for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders, by administering an **MC148P** protein (specifically MC148P1, MC148P2, MC148P3), are new. **MC148P** Proteins are derived from Molluscum Contagiosum Virus.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method (I), comprising administering, to a patient having atopic dermatitis, a composition comprising a **MC148P** protein which possesses atopic dermatitis inhibiting activity; and
(2) a kit (II), comprising multiple separately packaged portions of a composition adapted for treating atopic dermatitis comprising a **MC148P** protein which possesses atopic dermatitis inhibiting activity.

ACTIVITY - Dermatological; anti-allergic; anti-inflammatory; anti-asthmatic.

No quantitative biological data given.

MECHANISM OF ACTION - None given.

USE - The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders (claimed).

Dwg.0/5

ACCESSION NUMBER: 2002-138958 [18] WPIDS
DOC. NO. CPI: C2002-042742
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus.
DERWENT CLASS: B04 D16
INVENTOR(S): PASLIN, D A
PATENT ASSIGNEE(S): (PASL-I) PASLIN D A
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002009489	A1	20020124	(200218)*		15

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002009489	A1 Cont of	US 1999-426093	19991022
	Cont of	US 2000-624748	20000724
		US 2001-920897	20010801

PRIORITY APPLN. INFO: US 1999-426093 19991022; US
2000-624748 20000724; US
2001-920897 20010801

=> s atopic dermatittis
L2 0 ATOPIC DERMATITTIS

=> s atopic dermatitis
L3 69290 ATOPIC DERMATITIS

=> s l3 and treatment
L4 17102 L3 AND TREATMENT

=> s l4 and l1
L5 1 L4 AND L1

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 1 USPATFULL on STN

TI **Atopic dermatitis treatment** method

AB Compositions are provided for treating **atopic dermatitis**, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from Molluscum Contagiosum Virus (MCV), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of MCV proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other **MC148P** type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other **MC148P** type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to MCV proteings so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:16613 USPATFULL

TITLE: **Atopic dermatitis treatment**
method

INVENTOR(S): Paslin, David A., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	721		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:05:29 ON 27 MAY 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 11:06:03 ON 27 MAY 2004

L1 6 S MC148P OR MOLLUSCUM CONTAGIOSUM VIRAL PROTEIN
L2 0 S ATOPIC DERMATITTIS
L3 69290 S ATOPIC DERMATITIS
L4 17102 S L3 AND TREATMENT
L5 1 S L4 AND L1

=> s molluscum contagiosum viral protein?
 3 FILES SEARCHED...
 L6 0 MOLLUSCUM CONTAGIOSUM VIRAL PROTEIN?

=> s MCV?
 L7 6998 MCV?

=> s l7 and l4
 L8 34 L7 AND L4

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 34 USPATFULL on STN
 TI Transporters and ion channels
 AB The invention provides human transporters and ion channels (TRICH) and polynucleotides which identify and encode TRICH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TRICH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:70031 USPATFULL
 TITLE: Transporters and ion channels
 INVENTOR(S): Raumann, Brigitte E., Chicago, IL, UNITED STATES
 Thornton, Michael B., Oakland, CA, UNITED STATES
 Ding, Li, Creve Coeur, MO, UNITED STATES
 Yue, Henry, Sunnyvale, CA, UNITED STATES
 Tang, Y Tom, San Jose, CA, UNITED STATES
 Harland, Lee, Canterbury, UNITED KINGDOM
 Burford, Neil, Durham, CT, UNITED STATES
 Greene, Barrie D., San Francisco, CA, UNITED STATES
 Sanjanwala, Madhusudan M., Los Altos, CA, UNITED STATES
 Baughn, Mariah R., San Leandro, CA, UNITED STATES
 Yao, Monique G., Carmel, IN, UNITED STATES
 Yang, Junming, San Jose, CA, UNITED STATES
 Arvizu, Chandra S., San Jose, CA, UNITED STATES
 Gandhi, Ameena R., San Francisco, CA, UNITED STATES
 Hafalia, April J.A., Santa Clara, CA, UNITED STATES
 Tribouley, Catherine M., San Francisco, CA, UNITED STATES
 Chawla, Narinder K., Union City, CA, UNITED STATES
 Au-Young, Janice K., Brisbane, CA, UNITED STATES
 Walsh, Roderick T., Canterbury, UNITED KINGDOM
 Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
 Lu, Yan, Mountain View, CA, UNITED STATES
 Lu, Dyung Aina M., San Jose, CA, UNITED STATES
 Azimzai, Yalda, Oakland, CA, UNITED STATES
 Lal, Preeti G, Santa Clara, CA, UNITED STATES
 Elliott, Vicki S., San Jose, CA, UNITED STATES
 Nguyen, Danniel B., San Jose, CA, UNITED STATES
 Xu, Yuming, Mountain View, CA, UNITED STATES
 Seilhamer, Jeffrey J., Los Altos Hills, CA, UNITED STATES
 Borowsky, Mark L., Redwood City, CA, UNITED STATES
 Khan, Farrah A., Des Plaines, IL, UNITED STATES
 Kearney, Liam, San Francisco, CA, UNITED STATES
 Thangavelu, Kavitha, Mountain View, CA, UNITED STATES
 Das, Debopriya, Mountain View, CA, UNITED STATES
 Policky, Jennifer L., San Jose, CA, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004053258 A1 20040318
 APPLICATION INFO.: US 2003-332447 A1 20030922 (10)
 WO 2001-US21448 20010705
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Incyte Genomics Inc, Legal Department, 3160 Porter
 Drive, Palo Alto, CA, 94304
 NUMBER OF CLAIMS: 108
 EXEMPLARY CLAIM: 1
 LINE COUNT: 12231
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 34 USPATFULL on STN
 TI Novel nucleic acids and polypeptides
 AB The present invention provides novel nucleic acids, novel polypeptide
 sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:70018 USPATFULL
 TITLE: Novel nucleic acids and polypeptides
 INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES
 Liu, Chenghua, San Jose, CA, UNITED STATES
 Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053245	A1	20040318
APPLICATION INFO.:	US 2003-276774	A1	20030624 (10)
	WO 2001-US3800		20010205
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	18750		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 34 USPATFULL on STN
 TI 123 human secreted proteins
 AB The present invention relates to novel human secreted proteins and
 isolated nucleic acids containing the coding regions of the genes
 encoding such proteins. Also provided are vectors, host cells,
 antibodies, and recombinant methods for producing human secreted
 proteins. The invention further relates to diagnostic and therapeutic
 methods useful for diagnosing and treating diseases, disorders, and/or
 conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:58184 USPATFULL
 TITLE: 123 human secreted proteins
 INVENTOR(S): Fischer, Carrie L., Burke, VA, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Soppet, Daniel R., Centreville, VA, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Kyaw, Hla, Frederick, MD, UNITED STATES
 Li, Yi, Sunnyvale, CA, UNITED STATES
 Zeng, Zhizhen, Lansdale, PA, UNITED STATES
 LaFleur, David W., Washington, DC, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES
 Olsen, Henrik, Gaithersburg, MD, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Birse, Charles E., North Potomac, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004044191	A1	20040304
APPLICATION INFO.:	US 2001-973278	A1	20011010 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-227357, filed on 8 Jan 1999, GRANTED, Pat. No. US 6342581		
	Continuation-in-part of Ser. No. WO 1998-US13684, filed on 7 Jul 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-239899P	20001013 (60)
	US 1997-51926P	19970708 (60)
	US 1997-52793P	19970708 (60)
	US 1997-51925P	19970708 (60)
	US 1997-51929P	19970708 (60)
	US 1997-52803P	19970708 (60)
	US 1997-52732P	19970708 (60)
	US 1997-51931P	19970708 (60)
	US 1997-51932P	19970708 (60)
	US 1997-51916P	19970708 (60)
	US 1997-51930P	19970708 (60)
	US 1997-51918P	19970708 (60)
	US 1997-51920P	19970708 (60)
	US 1997-52733P	19970708 (60)
	US 1997-52795P	19970708 (60)
	US 1997-51919P	19970708 (60)
	US 1997-51928P	19970708 (60)
	US 1997-55722P	19970818 (60)
	US 1997-55723P	19970818 (60)
	US 1997-55948P	19970818 (60)
	US 1997-55949P	19970818 (60)
	US 1997-55953P	19970818 (60)
	US 1997-55950P	19970818 (60)
	US 1997-55947P	19970818 (60)
	US 1997-55964P	19970818 (60)
	US 1997-56360P	19970818 (60)
	US 1997-55684P	19970818 (60)
	US 1997-55984P	19970818 (60)
	US 1997-55954P	19970818 (60)
	US 1997-58785P	19970912 (60)
	US 1997-58664P	19970912 (60)
	US 1997-58660P	19970912 (60)
	US 1997-58661P	19970912 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 36492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 34 USPATFULL on STN
TI Modulation of CCR4 function
AB Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:51604 USPATFULL
TITLE: Modulation of CCR4 function
INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES

Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES
 Mahmud, Hossen, San Antonio, TX, UNITED STATES
 McMaster, Brian E., Mountain View, CA, UNITED STATES
 Medina, Julio C., San Carlos, CA, UNITED STATES
 Schall, Thomas J., Palo Alto, CA, UNITED STATES
 Xu, Feng, Palo Alto, CA, UNITED STATES
 Wang, Xuemei, San Mateo, CA, UNITED STATES
 Tularik Inc., So. San Francisco, CA (U.S. corporation)
 ChemoCentryx, Inc., San Carlos, CA (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004039035	A1	20040226
APPLICATION INFO.:	US 2003-654112	A1	20030902 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-975566, filed on 11 Oct 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240022P	20001011 (60)
	US 2001-293781P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	84	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2265	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 5 OF 34 USPATFULL on STN
 TI 98 human secreted proteins
 AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:45202 USPATFULL
 TITLE: 98 human secreted proteins
 INVENTOR(S): Komatsoulis, George A., Silver Spring, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES
 Duan, D. Roxanne, Bethesda, MD, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES
 LaFleur, David W., Washington, DC, UNITED STATES
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004034196	A1	20040219
APPLICATION INFO.:	US 2003-351334	A1	20030127 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-489847, filed on 24 Jan 2000, GRANTED, Pat. No. US 6476195		
	Continuation-in-part of Ser. No. WO 1999-US17130, filed on 29 Jul 1999, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-350898P 20020125 (60)
 US 1998-94657P 19980730 (60)
 US 1998-95486P 19980805 (60)
 US 1998-96319P 19980812 (60)
 US 1998-95454P 19980806 (60)
 US 1998-95455P 19980806 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 6 Drawing Page(s)
 LINE COUNT: 24589
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 34 USPATFULL on STN

TI Novel antibodies that bind to antigenic polypeptides, nucleic acids
 encoding the antigens, and methods of use
 AB Disclosed herein are nucleic acid sequences that encode polypeptides.
 Also disclosed are antibodies, which immunospecifically-bind to the
 polypeptide, as well as derivatives, variants, mutants, or fragments of
 the aforementioned polypeptide, polynucleotide, or antibody. The
 invention further discloses therapeutic, diagnostic and research methods
 for diagnosis, **treatment**, and prevention of disorders
 involving any one of these novel human nucleic acids, polypeptides, or
 antibodies, or fragments thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:24755 USPATFULL
 TITLE: Novel antibodies that bind to antigenic polypeptides,
 nucleic acids encoding the antigens, and methods of use
 INVENTOR(S): Alsobrook, John P., II, Madison, CT, UNITED STATES
 Anderson, David W., Branford, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Chapoval, Andrei, Branford, CT, UNITED STATES
 Edinger, Shlomit R., New Haven, CT, UNITED STATES
 Gerlach, Valerie, Branford, CT, UNITED STATES
 Gorman, Linda, Branford, CT, UNITED STATES
 Gunther, Erik, Branford, CT, UNITED STATES
 Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
 Kekuda, Ramesh, Norwalk, CT, UNITED STATES
 Lepley, Denise M., Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Liu, Xiaohong, Lexington, MA, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Miller, Charles E., Guilford, CT, UNITED STATES
 Millet, Isabelle, Milford, CT, UNITED STATES
 Padigar, Muralidhara, Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Pena, Carol E. A., New Haven, CT, UNITED STATES
 Rieger, Daniel K., Branford, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
 Vernet, Corine A.M., Branford, CT, UNITED STATES
 Voss, Edward Z., Wallingford, CT, UNITED STATES
 Zerhusen, Bryan D., Branford, CT, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004018594 A1 20040129
APPLICATION INFO.: US 2002-138588 A1 20020501 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-288395P	20010503 (60)
	US 2001-308901P	20010731 (60)
	US 2001-313388P	20010817 (60)
	US 2001-324757P	20010925 (60)
	US 2001-288900P	20010504 (60)
	US 2001-322802P	20010917 (60)
	US 2001-289087P	20010507 (60)
	US 2001-290753P	20010514 (60)
	US 2001-336882P	20011203 (60)
	US 2001-322701P	20010917 (60)
	US 2001-291189P	20010515 (60)
	US 2001-340305P	20011214 (60)
	US 2001-291243P	20010516 (60)
	US 2001-325682P	20010927 (60)
	US 2001-292001P	20010518 (60)
	US 2001-292374P	20010521 (60)
	US 2001-313851P	20010821 (60)
	US 2001-292587P	20010522 (60)
	US 2001-293107P	20010523 (60)
	US 2001-332129P	20011121 (60)
	US 2001-294110P	20010529 (60)
	US 2001-313937P	20010821 (60)
	US 2001-294434P	20010530 (60)
	US 2001-294827P	20010531 (60)
	US 2001-325314P	20010927 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Ph.D., Esq., MINTZ, LEVIN, COHN,
FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center,
Boston, MA, 02111

NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
LINE COUNT: 15349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 34 USPATFULL on STN
TI Novel nucleic acids and polypeptides
AB The present invention provides novel nucleic acids, novel polypeptide
sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:329843 USPATFULL
TITLE: Novel nucleic acids and polypeptides
INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Chen, Rui-Hong, Foster City, CA, UNITED STATES
Qian, Xiaohong B., San Jose, CA, UNITED STATES
Wang, Zhi Wei, Athens, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Cao, Yi-Cheng, Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232054	A1	20031218

APPLICATION INFO.: US 2002-291265 A1 20021108 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US2623, filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2001-922279, filed on 3 Aug 2001, ABANDONED Continuation of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED Continuation of Ser. No. US 2000-617746, filed on 17 Jul 2000, ABANDONED Continuation of Ser. No. US 2000-631451, filed on 3 Aug 2000, PENDING Continuation of Ser. No. US 2000-663870, filed on 15 Sep 2000, ABANDONED
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Renee S. Polizotto, Ph.D., NUVELO, 675 Almanor Avenue, Sunnyvale, CA, 94085
 NUMBER OF CLAIMS: 28
 EXEMPLARY CLAIM: 1
 LINE COUNT: 7928
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 34 USPATFULL on STN
 TI Preventive or therapeutic agent for pollen allergy, allergic rhinitis, **atopic dermatitis**, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof
 AB A method for prevention or therapy of pollen allergy, allergic rhinitis, **atopic dermatitis**, asthma or urticaria by administration of two kinds of crude drugs--seeds of Cucurbita moschata and flowers of Carthamus tinctorius--and at least one crude drug selected from Plantago asiatica, Lonicera japonica, Glycyrrhiza uralensis, Coix lachrymal-jobi var, ma-yuen, Zingiber officinale, Curcuma longa, Curcuma zedoaria and Artemisia argyi to a patient; and a health food for prevention, or improvement, or reduction of these symptoms containing the above substances.

ACCESSION NUMBER: 2003:282356 USPATFULL
 TITLE: Preventive or therapeutic agent for pollen allergy, allergic rhinitis, **atopic dermatitis**, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof
 INVENTOR(S): Yoshida, Satoshi, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198697	A1	20031023
APPLICATION INFO.:	US 2002-126779	A1	20020422 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	800		

L8 ANSWER 9 OF 34 USPATFULL on STN
 TI Compounds and methods for modulating CXCR3 function
 AB Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2003:174006 USPATFULL
 TITLE: Compounds and methods for modulating CXCR3 function
 INVENTOR(S): Schall, Thomas J., Palo Alto, CA, UNITED STATES
 Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES

PATENT ASSIGNEE(S): McMaster, Brian E., Mountain View, CA, UNITED STATES
ChemoCentryx, Inc., San Carlos, CA, UNITED STATES,
94070 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119854	A1	20030626
APPLICATION INFO.:	US 2002-279353	A1	20021023 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-648329, filed on 25 Aug 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151212P	19990827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1608	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 34 USPATFULL on STN

TI Diagnosis methods based on microcompetition for a limiting GABP complex

AB Microcompetition for GABP between a foreign polynucleotide and cellular GABP regulated genes is a risk factor associated with many chronic diseases such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present assays for the diagnosis of these chronic diseases. The assays are based on measuring the cellular copy number of the foreign polynucleotide, measuring the rate of complex formation between GABP and either the foreign polynucleotide, or a cellular GABP regulated gene, identifying modified expression of a cellular GABP regulated gene, or identifying modified activity of the gene product of a GABP regulated gene. The invention also presents other foreign polynucleotide-type assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:152692 USPATFULL

TITLE: Diagnosis methods based on microcompetition for a limiting GABP complex

INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003104358	A1	20030605
APPLICATION INFO.:	US 2002-219649	A1	20020815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Hanan Polansky, 3159 S. Winton Rd., Rochester, NY, 14623		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	14430		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 34 USPATFULL on STN

TI Compounds and methods for modulating cxcr3 function

AB The invention provides compounds and compositions of the formula:
##STR1##

wherein

the subscript n is an integer of from 0 to 4;

Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R.sup.1 is a member selected from the group consisting of substituted or unsubstituted (C.sub.5-C.sub.15)alkyl;

R.sup.2 is a member selected from the group consisting of substituted or unsubstituted (C.sub.1-C.sub.8)alkyl;

each R.sup.3 is independently a substituent selected from -halogen, --OR', --OC(O)R', --NR'R", --SR', --R', --CN, --NO.sub.2, --CO.sub.2R', --CONR'R", --C(O)R', --OC(O)NR'R", --NR"C(O)R', --NR"C(O).sub.2R', , --NR'--C(O)NR'R'", --NH--C(NH.sub.2).dbd.NH, --NR'C(NH.sub.2).dbd.NH, --NH--C(NH.sub.2).dbd.NR--, --S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R", --N.sub.3, --CH(Ph).sub.2, perfluoro(C.sub.1-C.sub.4)alkoxy, and perfluoro(C.sub.1-C.sub.4)alkyl, and where R', R" and R'" are independently selected from hydrogen, (C.sub.1-C.sub.8)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C.sub.1-C.sub.4)alkyl, and (unsubstituted aryl)oxy-(C.sub.1-C.sub.4)alkyl;

Y is a member selected from the group consisting of substituted or unsubstituted (C.sub.2-C.sub.8)alkylene and substituted or unsubstituted (C.sub.2-C.sub.8)heteroalkylene;

and Z is --NR.sup.4R.sup.5, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.8)alkyl.

These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, infectious disease, angiogenesis, and graft rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:123349 USPATFULL
TITLE: Compounds and methods for modulating cxcr3 function
INVENTOR(S): Schall, Thomas J., Palo Alto, CA, United States
Dairaghi, Daniel J., Palo Alto, CA, United States
McMaster, Brian E., Mountain View, CA, United States
PATENT ASSIGNEE(S): Chemocentryx, Inc., San Carlos, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6559160	B1	20030506
APPLICATION INFO.:	US 2000-648329		20000825 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151212P	19990827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Habte, Kahsay	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 34 USPATFULL on STN

TI CXCR3 antagonists

AB Compounds, compositions and methods that are useful in the **treatment** of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the **treatment** of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100123 USPATFULL

TITLE: CXCR3 antagonists

INVENTOR(S): Medina, Julio C., San Carlos, CA, UNITED STATES
Johnson, Michael G., San Francisco, CA, UNITED STATES
Li, An-Rong, So. San Francisco, CA, UNITED STATES
Liu, Jiwen, Belmont, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069234	A1	20030410
APPLICATION INFO.:	US 2002-164690	A1	20020606 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296499P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pennie & Edmonds, LLP, 3300 Hillview Avenue, Palo Alto, CA, 94304	
NUMBER OF CLAIMS:	135	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5271	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 34 USPATFULL on STN

TI **Treatment** methods based on microcompetition for a limiting GABP complex

AB Microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor associated with chronic disease such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present methods for the **treatment** of these chronic diseases. The methods are based on modifying such microcompetition, or the effect of such microcompetition on the cell. For instance, **treatment** may modify the cellular copy number of the foreign polynucleotide, change the rate of complex formation between GABP and either the foreign polynucleotide or the cellular GABP regulated gene, vary the expression of the cellular GABP regulated gene, or manipulate the activity of the gene product of the cellular GABP regulated gene. The invention also presents methods for **treatment** of chronic diseases resulting from other foreign polynucleotide-type disruptions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100088 USPATFULL

TITLE: **Treatment** methods based on microcompetition
for a limiting GABP complex
INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069199	A1	20030410
APPLICATION INFO.:	US 2002-219334	A1	20020815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Hanan Polansky, 3159 S. Winton Rd., Rochester, NY, 14623		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	14837		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L8 ANSWER 14 OF 34 USPATFULL on STN
TI Drug discovery assays based on microcompetition for a limiting GABP
complex
AB A recent discovery showed that microcompetition for GABP between a
foreign polynucleotide and a cellular GABP regulated gene is a risk
factor for some of the major chronic diseases, such as obesity, cancer,
atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other
autoimmune diseases. The invention uses this novel discovery to present
assays for screening compounds based on their effectiveness in
modulating such microcompetition, or the effects of such
microcompetition on the cell. The selected compounds can be used in
treatment of these chronic diseases. The invention also presents
assays for screening compounds that can be used in **treatment**
of chronic diseases resulting from other foreign polynucleotide-type
disruptions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:99511 USPATFULL
TITLE: Drug discovery assays based on microcompetition for a
limiting GABP complex
INVENTOR(S): Polansky, Hanan, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003068616	A1	20030410
APPLICATION INFO.:	US 2002-223050	A1	20020814 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Hanan Polansky, 3159 S. Winton Rd., Rochester, NY, 14623		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	14981		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L8 ANSWER 15 OF 34 USPATFULL on STN
TI SCCE modified transgenic mammals and their use as models of human
disease
AB Genetic evidence that an imbalance in the activity of serine proteases
can cause severe skin disease has recently been presented. The serine
protease SCCE is preferentially expressed in cornifying epithelia.

Increased expression of SCCE in psoriasis has previously been reported. Increased SCCE expression also in chronic lesions of **atopic dermatitis** is described herein. Transgenic mice expressing human SCCE in suprabasal epidermal keratinocytes were found to develop pathological skin changes with increased epidermal thickness, hyperkeratosis, dermal inflammation, and severe pruritus. The results strengthen the idea that SCCE may be involved in the pathogenesis of inflammatory skin diseases, and may offer a new therapeutic target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:94735 USPATFULL
 TITLE: SCCE modified transgenic mammals and their use as models of human disease
 INVENTOR(S): Hansson, Lennart, Pixbo, SWEDEN
 Egelrud, Torbjorn, Umea, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003066099	A1	20030403
APPLICATION INFO.:	US 2002-71214	A1	20020211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-218	20010209
	US 2001-267422P	20010209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2598	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 34 USPATFULL on STN
 TI 12 human secreted proteins
 AB The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:79303 USPATFULL
 TITLE: 12 human secreted proteins
 INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Kenny, Joseph J., Damascus, MD, UNITED STATES
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES
 Greene, John M., Gaitherburg, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Liu, Ding, Gaithersburg, MD, UNITED STATES
 Crocker, Paul R., Dundee, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055231	A1	20030320
APPLICATION INFO.:	US 2001-984130	A1	20011029 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-836353, filed		

on 18 Apr 2001, PENDING Continuation-in-part of Ser.
No. WO 1999-US25031, filed on 27 Oct 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-243792P	20001030 (60)
	US 2000-198407P	20000419 (60)
	US 1998-105971P	19981028 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	67 Drawing Page(s)	
LINE COUNT:	31982	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 17 OF 34 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the
treatment of inflammatory and immune conditions and diseases are
provided herein. In particular, the invention provides compounds which
modulate the expression and/or function of a chemokine receptor. The
subject methods are useful for the **treatment** of inflammatory
and immunoregulatory disorders and diseases, such as multiple sclerosis,
rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:79127 USPATFULL
TITLE: CXCR3 antagonists
INVENTOR(S): Medina, Julio C., San Carlos, CA, UNITED STATES
Johnson, Michael G., San Francisco, CA, UNITED STATES
Li, An-Rong, So. San Francisco, CA, UNITED STATES
Liu, Jiwen, Belmont, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055054	A1	20030320
APPLICATION INFO.:	US 2002-231895	A1	20020829 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-15532, filed on 11 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255241P	20001211 (60)
	US 2001-296499P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	135	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5270	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 18 OF 34 USPATFULL on STN
TI Agent for the anti-adhesion of skin pathogenic flora
AB Bacterial agents for preparing compositions which are for cosmetic,

pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents are extracts of a bacterium, or a bacterium and are selected for their adhesion to skin cells and anti-adhesion to pathogens of the cutaneous system. The invention also relates to compositions containing such agents.

ACCESSION NUMBER: 2003:70946 USPATFULL
TITLE: Agent for the anti-adhesion of skin pathogenic flora
INVENTOR(S): Baur, Markus, Stuttgart, GERMANY, FEDERAL REPUBLIC OF
Zink, Ralf, Le Mont Pelerin, SWITZERLAND
Auzanneau, Isabelle, Opio, FRANCE
Buffard, Karine, Sevres, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049231	A1	20030313
APPLICATION INFO.:	US 2002-177589	A1	20020621 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP12719, filed on 13 Dec 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-204489	19991222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WINSTON & STRAWN, PATENT DEPARTMENT, 1400 L STREET, N.W., WASHINGTON, DC, 20005-3502	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	833	

L8 ANSWER 19 OF 34 USPATFULL on STN

TI Ccr4 antagonists

AB Compounds, compositions and methods are provided that are useful in the **treatment** of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the **treatment** or prevention of inflammatory conditions and diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:24179 USPATFULL
TITLE: Ccr4 antagonists
INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES
Mahmud, Hossen, San Antonio, TX, UNITED STATES
Houze, Jonathan, San Mateo, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Medina, Julio C., San Carlos, CA, UNITED STATES
Wang, Xuemei, San Mateo, CA, UNITED STATES
Xu, Feng, Palo Alto, CA, UNITED STATES
Xu, Qingge, Burlingame, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik Inc., So. San Francisco, CA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018022	A1	20030123
APPLICATION INFO.:	US 2002-155605	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293781P	20010523 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Tularik Inc., Two Corporate Drive, So. San Francisco,
CA, 94080
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2212
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 34 USPATFULL on STN
TI Modulation of CCR4 function
AB Compounds and compositions are provided that bind to the CCR4 chemokine
receptor and which are useful for treating diseases associated with CCR4
activity, such as contact hypersensitivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:308398 USPATFULL
TITLE: Modulation of CCR4 function
INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES
Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES
Mahmud, Hossen, San Antonio, TX, UNITED STATES
McMaster, Brian E., Mountain View, CA, UNITED STATES
Medina, Julio C., San Carlos, CA, UNITED STATES
Schall, Thomas J., Palo Alto, CA, UNITED STATES
Xu, Feng, Palo Alto, CA, UNITED STATES
Wang, Xuemei, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik Inc., So. San Francisco, CA, UNITED STATES,
94080 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002173524	A1	20021121
APPLICATION INFO.:	US 2001-975566	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240022P	20001011 (60)
	US 2001-293781P	20010523 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 84
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 34 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the
treatment of inflammatory and immune conditions and diseases are
provided herein. In particular, the invention provides compounds which
modulate the expression and/or function of a chemokine receptor. The
subject methods are useful for the **treatment** of inflammatory
and immunoregulatory disorders and diseases, such as multiple sclerosis,
rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:301614 USPATFULL
TITLE: CXCR3 antagonists
INVENTOR(S): Medina, Julio C., San Carlos, CA, UNITED STATES
Johnson, Michael G., San Francisco, CA, UNITED STATES
Li, An-Rong, So. San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Liu, Jiwen, Belmont, CA, UNITED STATES
Xi Huang, Alan, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES
Tularik Inc., San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169159	A1	20021114
APPLICATION INFO.:	US 2001-15532	A1	20011211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255241P	20001211 (60)
	US 2001-296499P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	135	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5284	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 34 USPATFULL on STN
TI Method of inhibiting stenosis and restenosis
AB The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD 18 or CCR2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:198275 USPATFULL
TITLE: Method of inhibiting stenosis and restenosis
INVENTOR(S): Horvath, Christopher J., Taunton, MA, UNITED STATES
Rao, Patricia E., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106369	A1	20020808
	US 6663863	B2	20031216
APPLICATION INFO.:	US 2001-809739	A1	20010315 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-528267, filed on 17 Mar 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	36 Drawing Page(s)		
LINE COUNT:	2234		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 34 USPATFULL on STN

TI **Atopic dermatitis treatment** method

AB Compositions are provided for treating **atopic dermatitis**, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from Molluscum Contagiosum Virus (**MCV**), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of **MCV** proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other MC148P type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other MC148P type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to **MCV** proteins so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:16613 USPATFULL

TITLE: **Atopic dermatitis treatment**
method

INVENTOR(S): Paslin, David A., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	721		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 34 USPATFULL on STN

TI Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors

AB The invention concerns the use of a xanthine or a xanthine derivative having a meta-substituted acidic aryl at the 8-position to specifically modulate the physiologic role of adenosine activation of its various receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:179111 USPATFULL

TITLE: Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors

INVENTOR(S): Linden, Joel M., Charlottesville, VA, United States

PATENT ASSIGNEE(S): University of Virginia, Charlottesville, United States (U.S. corporation)
University of Virginia Patent Foundation,
Charlottesville, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303619	B1	20011016
APPLICATION INFO.:	US 1998-38991		19980312 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Cook, Rebecca		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		

NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 34 USPATFULL on STN
TI Therapeutic agent and method for feline AIDS virus infections and feline
atopic dermatitis
AB A therapeutic agent for feline immunodeficiency virus (FIV) infections,
(including the **treatment** of the anemia and chronic stomatitis
caused by infection with a FIV) comprising a feline interferon
preparation containing a feline interferon as a principal agent, and a
therapeutic method for FIV infections comprising administering a feline
interferon preparation containing a feline interferon as a principal
agent to a cat every day are disclosed. Furthermore, a therapeutic
method and agent for feline **atopic dermatitis** are
disclosed. The preferred feline interferon, is an ω -feline
interferon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:29533 USPATFULL
TITLE: Therapeutic agent and method for feline AIDS virus
infections and feline **atopic
dermatitis**
INVENTOR(S): Kajimoto, Tsunesuke, Kanagawa, Japan
Go, Ryougai, Houston, TX, United States
Suzuki, Makoto, Aichi, Japan
PATENT ASSIGNEE(S): Toray Industries, Inc., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6194381	B1	20010227
	WO 9818484		19980507
APPLICATION INFO.:	US 1998-101144		19981119 (9)
	WO 1997-JP3963		19971030
			19981119 PCT 371 date
			19981119 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-290601	19961031
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Gupta, Anish	
LEGAL REPRESENTATIVE:	Miller, Austin R.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	476	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 34 USPATFULL on STN
TI Antimicrobial determination of N-(aminoalkyl) and/or N-(Amidoalkyl)
dinitrogen heterocyclic compositions
AB Compositions are provided comprising novel di-nitrogen heterocycle
compounds containing N-(aminoalkyl) and/or N-(amidoalkyl) groups. An
additional situs of functionality is also provided. The compounds and
compositions of the invention are useful as antibacterial and other
pharmaceutical agents and as intermediates for preparation of other
pharmaceutical agents. In addition, compounds of the present invention
are useful as research reagents including employment as species for
effecting combinatorial synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:157183 USPATFULL
TITLE: Antimicrobial determination of N-(aminoalkyl) and/or
N-(Amidoalkyl) dinitrogen heterocyclic compositions
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
Kung, Pei Pei, Leucadia, CA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150129		20001121
APPLICATION INFO.:	US 1998-123139		19980727 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-688993, filed on 1 Aug 1996, now patented, Pat. No. US 5798360		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gitomer, Ralph		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1577		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 34 USPATFULL on STN
TI Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
AB This invention provides a conjugate comprising Substance P, and analogs thereof, and Saporin. This invention provides a method of reducing the perception of pain by a subject comprising administering to the subject an effective dose of the pharmaceutical composition of the conjugate comprising Substance P, and analogs thereof, and Saporin, so as to reduce the perception of pain by the subject. This invention provides a method of selectively destroying NK-1 receptor expressing cells in a subject comprising administering to the subject an effective dose of the conjugate comprising Substance P, and analogs thereof, and Saporin so as to selectively destroy NK-1 receptor expressing cells. Lastly, this invention provides a method for treating a NK-1 receptor associated disorder in a subject, which comprises administering to the subject an amount of the pharmaceutical composition comprising Substance P, and analogs thereof, and Saporin thereby treating the disorder associated with the NK-1 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:61574 USPATFULL
TITLE: Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
INVENTOR(S): Lappi, Douglas A., Del Mar, CA, United States
Wiley, Ronald G., Brentwood, TN, United States
PATENT ASSIGNEE(S): Advanced Targeting Systems, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6063758		20000516
APPLICATION INFO.:	US 1997-890157		19970709 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia		
ASSISTANT EXAMINER:	Borin, Michael		
LEGAL REPRESENTATIVE:	Phillips, Peter J.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 9 Drawing Page(s)		

LINE COUNT: 1109
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 34 USPATFULL on STN
TI N-(aminoalkyl)- and/or N-(amidoalkyl)-dinitrogen heterocycles
AB Compositions comprising novel di-nitrogen heterocycle compounds containing N-(aminoalkyl) and/or N-(amidoalkyl) groups are prepared. The compounds of the present invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:160035 USPATFULL
TITLE: N-(aminoalkyl)- and/or N-(amidoalkyl)-dinitrogen heterocycles
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
Kung, Pei Pei, Carlsbad, CA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5998419		19991207
APPLICATION INFO.:	US 1998-40787		19980318 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-691185, filed on 1 Aug 1996, now patented, Pat. No. US 5731438		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris, LLP		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1387		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 34 USPATFULL on STN
TI Meta-benzylic and alpha-amido compositions and methods for preparing same
AB Compositions comprising meta-benzylic compounds are prepared. The compositions are useful as antibacterial and as other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compositions of the present invention are useful as research reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:78876 USPATFULL
TITLE: Meta-benzylic and alpha-amido compositions and methods for preparing same
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5922872		19990713
APPLICATION INFO.:	US 1996-691139		19960801 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Achutamurthy, Ponnathapura		
ASSISTANT EXAMINER:	Ponnaluri, P.		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurt Mackiewicz & Norris, LLP		

NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 34 USPATFULL on STN
TI Di-nitrogen heterocycle compositions
AB Compositions comprising novel di-nitrogen heterocycle compounds containing at least one N-meta-substituted alkaryl group are prepared. The compounds of the present invention are useful as antibacterial and as other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:122244 USPATFULL
TITLE: Di-nitrogen heterocycle compositions
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
Kung, Pei Pei, Leucadia, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817489		19981006
APPLICATION INFO.:	US 1996-691149		19960801 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Achutamurthy, Ponnathapura		
ASSISTANT EXAMINER:	Ponnaluri, Padmashri		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	66		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1814		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 34 USPATFULL on STN
TI N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
AB Compositions are provided comprising novel di-nitrogen heterocycle compounds containing N-(aminoalkyl) and/or N-(amidoalkyl) groups. An additional situs of functionality is also provided. The compounds and compositions of the invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents including employment as species for effecting combinatorial synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:101651 USPATFULL
TITLE: N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
Kung, Pei Pei, Leucadia, CA, United States
PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5798360		19980825
APPLICATION INFO.:	US 1996-688993		19960801 (8)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 1543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 34 USPATFULL on STN
TI Complex chemical libraries
AB Compositions comprising novel chemical libraries are prepared. The compositions of the present invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:82543 USPATFULL
TITLE: Complex chemical libraries
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780241		19980714
APPLICATION INFO.:	US 1996-744020		19961105 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Green, Lora M.		
ASSISTANT EXAMINER:	Musto, Neal A.		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	2116		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 34 USPATFULL on STN
TI N-(aminoalkyl)-and/or N-(amidoalkyl)-dinitrogen heterocycles
AB Compositions comprising novel di-nitrogen heterocycle compounds containing N-(aminoalkyl) and/or N-(amidoalkyl) groups are prepared. The compounds of the present invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:31142 USPATFULL
TITLE: N-(aminoalkyl)-and/or N-(amidoalkyl)-dinitrogen heterocycles
INVENTOR(S): Cook, Phillip Dan, Vista, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
Kung, Pei Pei, Carlsbad, CA, United States
PATENT ASSIGNEE(S): ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5731438		19980324
APPLICATION INFO.:	US 1996-691185		19960801 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		

LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 34 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI Azathioprine in dermatological practice: An overview with special emphasis
on its use in non-bullous inflammatory dermatoses.

AB Azathioprine is employed for its immunosuppressive properties, as a
steroid-sparing agent or as monotherapy. Its most traditional clinical
indications are connective tissue diseases, vasculitis, post-transplant,
and immunobullous dermatoses. The main disadvantages of azathioprine
therapy are a delayed onset of action (6-8 weeks), and rare profound bone
marrow toxicity. Susceptibility to bone marrow toxicity is due to a
genetically determined metabolic defect (1 in 300). Patients at risk of
such toxicity may be identified by a Thiopurine methyltransferase enzyme
assay. We have undertaken a retrospective study, looking at the use of
azathioprine as monotherapy for non-bullous inflammatory, dermatoses. We
studied a total of 24 patients (10 male, 14 female). The dermatoses
comprised: atopic eczema (10), pompholyx (6), plaque psoriasis (6), and
chronic actinic dermatitis (2). All patients had severe refractory disease
warranting systemic second line therapy. The mean age was 49.4 years
(range 17-86 years). The starting dose of azathioprine was 100-150 mg/day,
and the maintenance dose 50-100 mg/day. The mean duration of
treatment was 33.5 months (range 1-132 months). Eighteen patients
(75%) showed a good to excellent sustained clinical response to
azathioprine. This response rate was evenly represented in the 4
dermatoses studied. The adverse reactions encountered were raised
MCV (6), leucopenia (2), raised hepatic enzymes (6), and dyspepsia
(4). Azathioprine had to be discontinued due to adverse reactions in 2
patients (dyspepsia, raised hepatic enzymes) followed by normalisation.
Other factors that potentially contributed to the observed adverse events
were present in 5 patients: alcoholism (2), erythromycin toxicity (1), and
malabsorption (2). Our study demonstrates the efficacy of azathioprine
monotherapy for severe atopic eczema, pompholyx, plaque psoriasis, and
chronic actinic dermatitis. Furthermore, azathioprine is a low cost and
generally well tolerated drug.

ACCESSION NUMBER: 2001088570 EMBASE

TITLE: Azathioprine in dermatological practice: An overview with
special emphasis on its use in non-bullous inflammatory
dermatoses.

AUTHOR: Scerri L.

CORPORATE SOURCE: L. Scerri, Sir Paul Boffa Hospital, Floriana, Malta

SOURCE: Advances in Experimental Medicine and Biology, (1999) 455/-
(343-348).

Refs: 11

ISSN: 0065-2598 CODEN: AEMBAP

COUNTRY: United States

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 013 Dermatology and Venereology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 5885822 A

L10: Entry 1 of 1

File: USPT

Mar 23, 1999

US-PAT-NO: 5885822

DOCUMENT-IDENTIFIER: US 5885822 A

TITLE: Method and system for growing molluscum contagiosum in xenografts to immunocompromised hosts

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Paslin</u> ; David A.	San Mateo	CA	94402	

US-CL-CURRENT: 435/235.1; 424/204.1, 424/232.1, 424/93.1, 435/239

Full	Title	Citation	Front	Review	Classification	Date	Reference	Searches	Attachments	Claims	KM/C	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	-------------	--------	------	----------

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
paslin.in.	1

Display Format: [CIT](#) [Change Format](#)

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
L9 and L10	0

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L11

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Thursday, May 27, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L11</u>	19 and L10	0	<u>L11</u>
<u>L10</u>	paslin.in.	1	<u>L10</u>
<u>L9</u>	L7 and l2	4449	<u>L9</u>
<u>L8</u>	l6 and L7	1	<u>L8</u>
<u>L7</u>	atopic dermatitis treatment	598216	<u>L7</u>
<u>L6</u>	6194381.pn.	1	<u>L6</u>
<u>L5</u>	(MC148P)	0	<u>L5</u>
<u>L4</u>	(atopic dermatitis) adj2 (MC148P)	0	<u>L4</u>
<u>L3</u>	treatment and L2	4290	<u>L3</u>
<u>L2</u>	atopic dermatitis adj2 MC148P	4449	<u>L2</u>
<u>L1</u>	5885822.pn.	1	<u>L1</u>

END OF SEARCH HISTORY